The spike protein of the coronavirus, or SARS-CoV-2, binds to ACE2, a receptor on the host cells, which allows the virus to enter the cells and infect it. Binding is the first step for infection, and ...

Researchers at Umeå University have discovered that the SARS-CoV-2 variant omicron has developed a stronger binding to human ...

Scientists from UNIGE have developed synthetic molecules that mimic antibodies. They could revolutionize the treatment of ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin ... the researchers analyzed the RBD structure to identify target sites. Starting with LCB1, a ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

Scientists have identified a new pair of antibodies that could fend off multiple COVID-19 variants ... can attach to the spike protein's receptor-binding domain, or RBD, thus preventing the ...

The influenza M2 viroporin is already a clinically approved antiviral drug target. In other coronaviruses, the E protein viroporin which is involved in growth, could be a potential target for COVID-19 ...

In late 2020, the decision was made to abandon further trials of a COVID-19 vaccine being developed ... each consisting of a receptor-binding subunit, S1, and a subunit responsible for fusion ...